In 2009 Pfizer was in stage 3 of clinical trials.
The results were promising.
They dropped it.
2009????
I've always believed that Fibromyalgia was not on anyone's top ten list. It's been either a garbage can diagnosis or just totally dismissed as an illness. I guess there's just not enough money to be made in treating patients that live in pain.
Please forgive my cynicism. I used to say that if doctors got the crap beat out of them with a baseball bat and had to live with that pain for weeks, months and years maybe then they would understand what living with chronic pain is like.
Esreboxetine.
Ever heard of it?
Neither had I.
Researchers published that it linked this drug to reductions in pain and improved patients scores on the Fibromyalgia questionnaire. Even though this drug was thought to be promising and was through phase 3 of clinical trials neither Pfizer or any other company went forward with it.
Until now.
Axsome Theraputics plans to submit a new drug application for AXS-14 later this year for a potential treatment of Fibromyalgia. It will include the phase 2 and 3 data that show a significant improvement compared to the placebo.
The best part?
Not the fact that it will help patients.
That would be too easy.
Try Axsome had to pay Pfizer 3 million bucks.
Plus, Pfizer gets 8 million of Axsome stock.
But wait!
There's more!
Pfizer gets first right of negotiation in future transactions regarding AXS-14 and an antidepressant medication they castoff now called AXS-12.
Not bad for a castoff drug they didn't want.
I have questions though.
Reboxetine is for treating major depression. So....where does esreboxetine fall in this category?
Reboxetine is not available in the US but it is in Europe and from what I read there are a ton of icky side effects. Pfizer successfully used animal models but human one were not as successful. I'll list the link below to show why it is so controversial in Europe.
But back to esreboxetine....
Will it work?
I don't think the votes are in yet.......
Back to square one.
Psycom.net/reboxetine
